Patient P-02244

Synthetic patientMETA-24 · Day 129 · 35–44 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Declining

Tolerance

Stable

GI state

Deteriorating

Inflammatory state

Deteriorating

Nutritional resilience

Declining

Discontinuation risk

82%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 47 NP-02 recommended — Dietary Support Protocol NP-02
Day 48 Patient accepted — Started NP-02 in the companion
Day 58 No meaningful change — Dietary Support Protocol NP-02
Day 62 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 71 GI-04 recommended — GI Support Protocol GI-04
Day 72 Patient accepted — Started GI-04 in the companion
Day 80 GI symptom burden −25% vs expected — GI Support Protocol GI-04
Day 86 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 62.

Primary contributors, last 14 days

GI instability+13
Treatment adherence-11
Inflammatory activity+7
Nutritional resilience-5
Toxicity-3

What helped?

Dietary Support Protocol NP-02Day 47
Result: no meaningful change
GI Support Protocol GI-04Day 71
Result: symptom burden −25%

LIFE OS recommendation

Monitoring Escalation ME-01

92%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

33 min

stable · -1.7 vs previous 14 d

Sleep duration

Wearable

6.2 h

stable · -0.0 vs previous 14 d

Energy level

Daily log

3/10

stable · -0.1 vs previous 14 d

Steps

Wearable

4,229

stable · -102 vs previous 14 d

GI burden

Companion

52.6/100

worsening · +2.9 vs previous 14 d

Adherence

Companion

48.5 %

worsening · -17.2 vs previous 14 d

Sleep quality

Wearable

29.7/100

stable · +0.2 vs previous 14 d

Glucose, CGM daily mean

CGM

143 mg/dL

stable · +3.9 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 31 from the failing basin, 56 from restoration.

Would help

ME-01 Monitoring Escalation
100% improved among 42 similar · onset 3 d · confidence 80%
SC-12 Supportive Compound
69% improved among 26 similar · onset 6 d · confidence 80%
CR-01 Clinician Review
100% improved among 6 similar · onset 5 d · confidence 80%
More protein
GI -5.9 next day on high-intake days · n 20

Would not help

NP-02 Dietary Support Protocol
already tried, no meaningful change
Keep caffeine low
GI +6 next day on high-intake days · n 21
Keep fat low
GI +5.8 next day on high-intake days · n 23
Keep ultra-processed low
GI +5.4 next day on high-intake days · n 25

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Caffeine
+6detractor · 95%
Protein
-5.9supporter · 95%
Dietary fat load
+5.8detractor · 95%
Ultra-processed food
+5.4detractor · 95%
Insoluble fibre
+4.1detractor · 95%
Simple carbohydrates
+2.8no signal · 53%
Histamine load
+0.5no signal · 15%
Alcohol
0no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 37/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 53
- WearableHRV 25 ms, trending down
Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 43
Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 53 and rising
Autonomic recovery ↓45
- WearableResting HR 84 bpm
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Poor metabolizer
Higher exposure at standard dose
GLP1R rs6923761 A
Altered receptor sensitivity

Microbiome

Shannon diversity 1.9 · butyrate capacity 37/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 26 ms
Sleep: 6.0 h
Steps: 5,176
Resting HR: 82 bpm

Daily log: GI score 53, nutritional resilience 46, adherence 49.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02693	54%	S14	ME-01	improved	41
P-02132	53%	S14	SC-12	improved	40
P-02118	52%	S14	GI-04	improved	47
P-02363	49%	S14	GI-04	improved	49
P-02574	49%	S14	ME-01	improved	45
P-02236	46%	S14	GI-04	improved	45
P-02268	46%	S14	GI-04	improved	43
P-02535	46%	S14	SC-12	improved	50
P-02381	45%	S14	SC-12	improved	52
P-02670	45%	S14	SC-12	improved	45
P-02002	44%	S14	GI-04	improved	47
P-02320	44%	S14	NP-02	improved	50